Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas

Journal of Molecular Diagnostics

Volumn 13, Issue 6, 2011, Pages 669-677

  Tian, Yongji ^a,g   Rich, Benjamin E ^a   Vena, Natalie ^a   Craig, Justin M ^a   MacConaill, Laura E ^a   Rajaram, Veena ^b   Goldman, Stewart ^b   Taha, Hala ^c   Mahmoud, Madeha ^c   Ozek, Memet ^d   Sav, Aydin ^d   Longtine, Janina A ^e   Lindeman, Neal I ^e   Garraway, Levi A ^a   Ligon, Azra H ^a   Stiles, Charles D ^a   Santagata, Sandro ^e,f   Chan, Jennifer A ^e,h   Kieran, Mark W ^a,f   Ligon, Keith L ^a,e,f  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b CHILDREN'S MEMORIAL HOSPITAL   (United States)

^c CHILDREN S CANCER HOSPITAL   (Egypt)

^d ACIBADEM UNIVERSITY   (Turkey)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f BOSTON CHILDREN S HOSPITAL   (United States)

^g CAPITAL MEDICAL UNIVERSITY   (China)

^h UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; FORMALDEHYDE; PARAFFIN;

ARTICLE; BRAF GENE; CANCER GRADING; CHILDHOOD CANCER; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; EMBEDDING; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE DUPLICATION; GENE MUTATION; GLIOMA; HISTOLOGY; HUMAN; HUMAN TISSUE; KIAA 1549 GENE; PILOCYTIC ASTROCYTOMA; POLYMERASE CHAIN REACTION; PYROSEQUENCING; SENSITIVITY AND SPECIFICITY;

EID: 82955249323     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmoldx.2011.07.002     Document Type: Article

References (23)

1. Louis D, Ohgaki H, Wiestler O, and Cavanese W: WHO Classification of Tumours of the Central Nervous System, 3rd ed. Edited by F Bosman, et al. Lyon, International Agency for Research on Cancer (IARC), 2007
2. Dhomen N, Marais R: New insight into BRAF mutations in cancer. Curr Opin Genet Dev 2007, 17:31-39 (Pubitemid 46109299)
3. Jones DT, Kocialkowski S, Liu L, Pearson DM, Backlund LM, Ichimura K, Collins VP: Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 2008, 68:8673-8677
4. Pfister S, Janzarik WG, Remke M, Ernst A, Werft W, Becker N, Toedt G, Wittmann A, Kratz C, Olbrich H, Ahmadi R, Thieme B, Joos S, Radlwimmer B, Kulozik A, Pietsch T, Herold-Mende C, Gnekow A, Reifenberger G, Korshunov A, Scheurlen W, Omran H, Lichter P: BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest 2008, 118:1739-1749 (Pubitemid 351632377)
5. Sievert AJ, Jackson EM, Gai X, Hakonarson H, Judkins AR, Resnick AC, Sutton LN, Storm PB, Shaikh TH, Biegel JA: Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density singlenucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene. Brain Pathol 2009, 19:449-458
6. Forshew T, Tatevossian RG, Lawson AR, Ma J, Neale G, Ogunkolade BW, Jones TA, Aarum J, Dalton J, Bailey S, Chaplin T, Carter RL, Gajjar A, Broniscer A, Young BD, Ellison DW, Sheer D: Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol 2009, 218:172-181
7. Cin H, Meyer C, Herr R, Janzarik WG, Lambert S, Jones DT, Jacob K, Benner A, Witt H, Remke M, Bender S, Falkenstein F, Van Anh TN, Olbrich H, von Deimling A, Pekrun A, Kulozik AE, Gnekow A, Scheurlen W, Witt O, Omran H, Jabado N, Collins VP, Brummer T, Marschalek R, Lichter P, Korshunov A, Pfister SM: Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathol 2011, 121:763-774
8. Jones DT, Kocialkowski S, Liu L, Pearson DM, Ichimura K, Collins VP: Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549: BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene 2009, 28:2119-2123
9. Tatevossian RG, Lawson AR, Forshew T, Hindley GF, Ellison DW, Sheer D: MAPK pathway activation and the origins of pediatric lowgrade astrocytomas. J Cell Physiol 2010, 222:509-514
10. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al.: Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954 (Pubitemid 34716871)
11. Michaloglou C, Vredeveld LC, Mooi WJ, Peeper DS: BRAF(E600) in benign and malignant human tumours. Oncogene 2008, 27:877-895 (Pubitemid 351225383)
12. MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, Davis M, Yao K, Hanna M, Mondal C, Luongo L, Emery CM, Baker AC, Philips J, Goff DJ, Fiorentino M, Rubin MA, Polyak K, Chan J, Wang Y, Fletcher JA, Santagata S, Corso G, Roviello F, Shivdasani R, Kieran MW, Ligon KL, Stiles CD, Hahn WC, Meyerson ML, Garraway LA: Profiling critical cancer gene mutations in clinical tumor samples. PLoS One 2009, 4:e7887
13. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Neale G, Keir ST, Carol H, Lock R, Phelps D, Kang MH, Reynolds CP, Maris JM, Billups C, Smith MA: Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2010, 55:668-677
14. Eisenhardt AE, Olbrich H, Roring M, Janzarik W, Van Anh TN, Cin H, Remke M, Witt H, Korshunov A, Pfister SM, Omran H, Brummer T: Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma. Int J Cancer 2010, doi: 10.1002/ijc.25893
15. Dias-Santagata D, Lam Q, Vernovsky K, Vena N, Lennerz JK, Borger DR, Batchelor TT, Ligon KL, Iafrate AJ, Ligon AH, Louis DN, Santagata S: BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One 2011, 6:e17948
16. Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold- Mende C, Schmieder K, Wesseling P, Mawrin C, Hasselblatt M, Louis DN, Korshunov A, Pfister S, Hartmann C, Paulus W, Reifenberger G, von Deimling A: Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 2011, 121:397-405
17. Schiffman JD, Hodgson JG, VandenBerg SR, Flaherty P, Polley MY, Yu M, Fisher PG, Rowitch DH, Ford JM, Berger MS, Ji H, Gutmann DH, James CD: Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res 2010, 70:512-519
18. Whittaker S, Menard D, Kirk R, Ogilvie L, Hedley D, Zambon A, Lopes F, Preece N, Manne H, Rana S, Lambros M, Reis-Filho JS, Marais R, Springer CJ: A novel, selective, and efficacious nanomolar pyridopyrazinone inhibitor of V600EBRAF. Cancer Res 2010, 70:8036-8044
19. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al.: Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAFmutant melanoma. Nature 2010, 467:596-599
20. Holland PM, Abramson RD, Watson R, Gelfand DH: Detection of specific polymerase chain reaction product by utilizing the 5′-3′ exonuclease activity of Thermus aquaticus DNA polymerase. Proc Natl Acad Sci U S A 1991, 88:7276-7280 (Pubitemid 21915133)
21. Yeo G, Holste D, Kreiman G, Burge CB: Variation in alternative splicing across human tissues. Genome Biol 2004, 5:R74
22. Ghigna C, Valacca C, Biamonti G: Alternative splicing and tumor progression. Curr Genomics 2008, 9:556-570
23. Jensen K, Shiels C, Freemont PS: PML protein isoforms and the RBCC/TRIM motif. Oncogene 2001, 20:7223-7233 (Pubitemid 33105011)